Haemonetics Corporation (HAE)

Operating return on assets (Operating ROA)

Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019
Operating income (ttm) US$ in thousands 164,883 170,195 167,496 178,925 156,033 139,977 132,349 110,127 80,750 40,376 45,150 79,422 89,747 136,929 137,411 128,368 103,351 101,200 88,613 64,950
Total assets US$ in thousands 2,195,590 2,200,430 2,011,280 1,962,260 1,934,820 1,878,070 1,865,110 1,820,530 1,859,730 1,831,380 1,801,500 1,794,190 1,819,920 1,318,070 1,418,170 1,433,170 1,267,110 1,237,750 1,190,540 1,259,610
Operating ROA 7.51% 7.73% 8.33% 9.12% 8.06% 7.45% 7.10% 6.05% 4.34% 2.20% 2.51% 4.43% 4.93% 10.39% 9.69% 8.96% 8.16% 8.18% 7.44% 5.16%

March 31, 2024 calculation

Operating ROA = Operating income (ttm) ÷ Total assets
= $164,883K ÷ $2,195,590K
= 7.51%

Haemonetics Corporation's operating return on assets (operating ROA) has exhibited fluctuations over the past several quarters. The trend shows an improvement in performance from the fourth quarter of 2019 to the first quarter of 2020 with operating ROA increasing from 5.16% to 10.39%. This was followed by a gradual decline in the metric until the second quarter of 2021.

However, from the third quarter of 2021 onwards, there has been a significant uptrend in operating ROA, reaching a peak of 9.12% in the second quarter of 2023. Overall, the company's operating ROA has ranged from a low of 2.20% in the first quarter of 2022 to a high of 10.39% in the first quarter of 2020.

The recent values of operating ROA indicate relatively healthy profitability levels compared to previous periods, with the metric hovering around the 7-9% range. It is important for investors and stakeholders to monitor this ratio to assess the company's efficiency in generating profits from its assets over time.


Peer comparison

Mar 31, 2024